Equities Analysts Set Expectations for CTMX Q2 Earnings

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Equities researchers at HC Wainwright reduced their Q2 2025 earnings estimates for CytomX Therapeutics in a research report issued on Thursday, May 15th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will earn $0.02 per share for the quarter, down from their previous estimate of $0.20. HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for CytomX Therapeutics' current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics' Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.23 EPS, Q1 2026 earnings at $0.01 EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.00 EPS and Q4 2026 earnings at ($0.02) EPS.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The firm had revenue of $50.92 million during the quarter, compared to analyst estimates of $35.42 million. During the same quarter in the prior year, the business posted $0.17 earnings per share.

Several other research firms have also issued reports on CTMX. Piper Sandler increased their price objective on shares of CytomX Therapeutics from $2.50 to $5.00 and gave the stock an "overweight" rating in a research report on Thursday. Wedbush reissued an "outperform" rating and issued a $6.00 price objective (up previously from $5.00) on shares of CytomX Therapeutics in a research report on Monday, May 12th. Finally, StockNews.com raised shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Tuesday, May 13th.

CytomX Therapeutics Stock Up 1.5%

CytomX Therapeutics stock opened at $2.03 on Monday. CytomX Therapeutics has a 52-week low of $0.40 and a 52-week high of $2.55. The firm has a fifty day moving average of $0.82 and a 200-day moving average of $0.89. The firm has a market capitalization of $163.66 million, a P/E ratio of 11.94 and a beta of 1.11.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Woodline Partners LP purchased a new position in shares of CytomX Therapeutics in the first quarter valued at $1,054,000. Goldman Sachs Group Inc. purchased a new position in shares of CytomX Therapeutics in the first quarter valued at $39,000. RA Capital Management L.P. purchased a new position in shares of CytomX Therapeutics in the first quarter valued at $636,000. Velan Capital Investment Management LP boosted its stake in shares of CytomX Therapeutics by 114.3% in the first quarter. Velan Capital Investment Management LP now owns 75,000 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 40,000 shares during the period. Finally, Aspire Growth Partners LLC boosted its stake in shares of CytomX Therapeutics by 126.2% in the first quarter. Aspire Growth Partners LLC now owns 92,254 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 51,474 shares during the period. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.